Navigation Links
Pisgah Laboratories, Inc. Scores a Triple Play in the World Series Against Prescription Drug Abuse
Date:11/12/2012

PISGAH FOREST, N.C., Nov. 12, 2012 /PRNewswire/ -- Pisgah Laboratories, Inc. (www.pisgahlabs.com) has recently received three Notices of Allowance for United States Patents related to its abuse deterrent medications platform. Earlier this year, Pisgah obtained US Patent 8,211,905 emanating from work conducted at their facility in Pisgah Forest, NC. The latest Notices represent additional milestones to what Pisgah believes will be significant advances in the war on drug abuse. Two of the Notices relate to "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose-Dumping Properties," and the third is entitled, "Salts of Physiologically Active and Psychoactive Alkaloids and Amines Simultaneously Exhibiting Bioavailability and Abuse Resistance." Pisgah indicates these patent allowances are the foundation to what they expect to be a broad intellectual property portfolio encompassing narcotics, obesity treatment drugs, and high abuse-potential medications used to treat attention deficit hyperactivity disorder, AD(H)D.

Pisgah's approach to counter drug abuse is to re-vamp the chemistry of abused medications so as to remove the features which enable abuse—while still retaining the intended medical benefit when the drug is used properly. To do this, Pisgah has modified the active ingredient in the drug product to have properties which are difficult to extract from the dosage form (the pill) and to yield a drug substance that is ineffective when used illicitly in "alternate routes of administration." This chemical and physical selectivity imparted to the drug substance—the active pharmaceutical ingredient (API), now enables drug product manufacturers to prepare specialty pharmaceuticals with highly refined features and benefits.    

Pisgah's president and CEO, Bill Bristol commented, "The broad applicability of these innovations offers a new hope for defeating the drug abuse cycle while revitalizing an underserved market." Indeed, Pisgah's approach allows for advancement on many fronts supporting abuse-deterrent product development for a range of pain, AD(H)D and bariatric medications. As bureaucracy and regulations have strangled an otherwise vibrant drug development industry, Pisgah's inventions offer a scientific underpinning to the FDA's objectives to reduce drug abuse and provide a predictable and viable financial mechanism to potential patent licensees.

Bristol further commented, "Tangible accomplishments such as allowed patents, animal studies and IND filings serve to further validate the technology and make it a credible business venture with a high probability of success." And, Pisgah is doing their part to deliver on a complex set of expectations by internally funding the product development work on an abuse deterrent hydrocodone product. As each step of product development progresses, new quality standards are achieved and the unique features and benefits of the technology are confirmed. Bristol's only lament is the absence of multiple products being developed simultaneously in order to hasten these valuable products to market. He concedes that large pharmaceutical companies are hesitant to commit to new opportunities until essentially all risks are removed. This reluctance is enhanced by global market uncertainties and the poor business climate created by enormous government deficits. Pisgah's product development activities are self-funded and clearly reflect this company's commitment to improving the safety of beneficial medications while pursuing an entrepreneurial return. As Pisgah continues on its progression of patent allowances and product development, it's their intention to collaborate in licensing arrangements to help fill empty pipelines.

For more information or to discuss the available opportunities, contact:

Todd Stamps
Business and Market Development
803-212-8224

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com


'/>"/>
SOURCE Pisgah Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
2. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
3. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
4. SafeCode Drug Technologies Launches New Website With Product Video Demonstrating the Worlds Next Generation Application for Drug Safety Administration
5. Projecis Signs "Top 5" Worldwide Generic Drug Maker and Niche European CRO as Sales Climb for Software Company
6. Harwood Feffer LLP Announces Investigation of PSS World Medical, Inc.
7. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
8. World Alzheimers Report 2012 Reveals Stigma and Social Exclusion are Major Barriers for People With Dementia and Their Carers
9. Disney World Theme Parks Latest Addition
10. ClosedWon Launches QuickQuote at Dreamforce 2012 on Salesforce.coms AppExchange, the Worlds Most Popular Cloud Marketplace for Social Apps for Business
11. U.S. Veterans Discover Koreas World-Class Health and Wellness Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):